The structure/function of apoprotein A-I mimetic peptides: An update

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 21, Issue 2, 2014, Pages 129-133

  Getz, Godfrey S ^a   Reardon, Catherine A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

apoprotein A I mimetic peptides; intestine; lysophosphatidic acid; transgenic tomatoes

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN;

ARTHRITIS; ASTHMA; ATHEROSCLEROSIS; DRUG DELIVERY SYSTEM; DRUG MECHANISM; HUMAN; HYPERLIPIDEMIA; INFLUENZA; INSULIN DEPENDENT DIABETES MELLITUS; LIVER FIBROSIS; NEPHRITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PNEUMONIA; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SCLERODERMA; SEPSIS;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; BIOMIMETIC MATERIALS; DIET; FEMALE; HUMANS; INFLAMMATION; INTESTINE, SMALL; LYCOPERSICON ESCULENTUM; LYSOPHOSPHOLIPIDS; MALE; PLANTS, GENETICALLY MODIFIED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84896878003     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000045     Document Type: Review

References (25)

1. Anantharamaiah GM, Jones JL, Brouillette CG, et al. Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem 1985; 260:10248-10255
2. Mendez AJ, Anantharamaiah GM, Segrest JP, OramJF. Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. J Clin Invest 1994; 94:1698-1705
3. Wool GD, Reardon CA, Getz GS. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially antiatherogenic properties. J Lipid Res 2008; 49:1268-1283
4. Sethi AA, Stonik JA, Thomas F, et al. Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J Biol Chem 2008; 283:32273-32282
5. Getz GS, Reardon CA. Apolipoprotein A-I and A-I mimetic peptides: A role in atherosclerosis. J Inflamm Res 2011; 4:83-92
6. Getz GS, Reardon CA. HDL apoprotein mimetic peptides as anti-inflammatory molecules. In: Komodo T, editor. The HDL Handbook, 2nd ed. Waltham, MA: Academic Press/Elsevier; 2013
7. D'Souza W, Stonik JA, Murphy A, et al. Structure/function relationships of apolipoprotein a-I mimetic peptides: Implications for antiatherogenic activities of high-density lipoprotein. Circ Res 2010; 107:217-227
8. Ditiatkovski M, D'Souza W, Kesani R, et al. An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice. PLoS One 2013; 8:e68802
9. Navab M, Reddy ST, Anantharamaiah GM, et al. Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J Lipid Res 2011; 52:1200-1210
10. Navab M, Reddy ST, Anantharamaiah GM, et al. D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice. J Lipid Res 2012; 53:437-445
11. Van Lenten BJ, Wagner AC, Jung CL, et al. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res 2008; 49:2302-2311
12. Chattopadhyay A, Navab M, Hough G, et al. A novel approach to oral apoA-I mimetic therapy. J Lipid Res 2013; 54:995-1010
13. Getz GS, Reardon CA. ApoA-I mimetics: Tomatoes to the rescue. J Lipid Res 2013; 54:878-880
14. Navab M, Hough G, Buga GM, et al. Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. J Lipid Res 2013; 54:3403-3418
15. Remaley AT. Tomatoes, lysophosphatidic acid, and the small intestine: New pieces in the puzzle of apolipoprotein mimetic peptides? J Lipid Res 2013; 54:3223-3226
16. Schober A, Siess W. Lysophosphatidic acid in atherosclerotic diseases. Br J Pharmacol 2012; 167:465-482
17. Navab M, Anantharamaiah GM, Hama S, et al. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005; 25:1426-1432
18. Yao X, Vitek MP, Remaley AT, Levine SJ. Apolipoprotein mimetic peptides: A new approach for the treatment of asthma. Front Pharmacol 2012; 3:37
19. Fisher EA, Feig JE, Hewing B, et al. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2012; 32:2813-2820
20. Mishra VK, Palgunachari MN, McPherson DT, Anantharamaiah GM. Lipid complex of apolipoprotein A-I mimetic peptide 4F is a novel platform for paraoxonase-1 binding and enhancing its activity and stability. Biochem Biophys Res Commun 2013; 430:975-980
21. White CR, Datta G, Buck AK, et al. Preservation of biological function despite oxidative modification of the apolipoprotein A-I mimetic peptide 4F. J Lipid Res 2012; 53:1576-1587
22. Wang W, Xu H, Shi Y, et al. Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. J Lipid Res 2010; 51:2560-2570
23. Madenspacher JH, Azzam KM, Gong W, et al. Apolipoproteins and apolipoprotein mimetic peptides modulate phagocyte trafficking through chemotactic activity. J Biol Chem 2012; 287:43730-43740
24. Yao X, Dai C, Fredriksson K, et al. 5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma. J Immunol 2011; 186:576-583
25. White CR, Smythies LE, Crossman DK, et al. Regulation of pattern recognition receptors by the apolipoprotein A-I mimetic peptide 4F. Arterioscler Thromb Vasc Biol 2012; 32:2631-2639